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NMR spectroscopymponent of senile plaques (SP) which accumulates in AD (Alzheimer's disease)
brain. Reports from different laboratories indicate that anesthetics interact with Aβ peptide and induce Aβ
oligomerization. The molecular mechanism of Aβ peptide interactions with these anesthetics was not
determined. We report molecular details for the interactions of uniformly 15N labeled Aβ40 with different
anesthetics using 2D nuclear magnetic resonance (NMR) experiments. At high concentrations both isoﬂurane
and propofol perturb critical amino acid residues (G29, A30 and I31) of Aβ peptide located in the hinge region
leading to Aβ oligomerization. In contrast, these three speciﬁc residues do not interact with thiopental and
subsequently no Aβ oligomerization was observed. However, studies with combined anesthetics (thiopental
and halothane), showed perturbation of these residues (G29, A30 and I31) and subsequently Aβ
oligomerization was found. Perturbation of these speciﬁc Aβ residues (G29, A30 and I31) by different
anesthetics could play an important role to induce Aβ oligomerization.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a neurodegenerative disease affecting
millions of elderly people worldwide and AD is characterized by
amyloid deposits in the brain. Although AD was discovered one
century ago, the molecular cause of AD is not yet known. Researchers
have discovered several risk factors associated with AD, but at present
there is no cure. Amyloid deposits consist of either the 40-residue
containing Aβ40 and/or the 42-residue containing Aβ42 peptide.
Aβ42 has a higher aggregation tendency compared to Aβ40 [1] and
Aβ42 peptide is more pathogenic than Aβ40 [1,2]. The structural
alteration of Aβ leading to oligomerization is believed to play an
important role in AD [3].
At clinically relevant concentrations of halothane and isoﬂurane,
Aβ peptide oligomerization and cytotoxicity was reported in rat
pheochromocytoma cells [4]. Biophysical studies involving size-
exclusion chromatography, analytical ultracentrifugation and
photo-induced cross-linking experiments indicated the inhaled
anesthetics halothane and isoﬂurane facilitate intermediate Aβ
oligomer formation [5]. Halothane induced more amyloid plaque in
transgenic mice with AD pathology [6]. It is also reported that Aβ
oligomers generate in situ altered neuronal function [7]. However,
the speciﬁc binding site of these anesthetics as well as molecular
mechanism of anesthetic-induced Aβ oligomerization is unknown.iety meeting, 2007.
lp@upmc.edu (P.K. Mandal).
l rights reserved.We previously reported that halothane interacts with amino acid
residues (G29, A30 and I31) in the critical hinge region of Aβ40
and Aβ42 using nuclear magnetic resonance (NMR) spectroscopic
studies conducted in a membrane mimic environment consisting
of sodium dodecyl sulphate (SDS) [8]. The oligomerization
propensity of Aβ42 is much higher than Aβ40. Hence Aβ40 is
better suitable than Aβ42 for time dependence NMR studies.
In this report we investigate the speciﬁcity of other anesthetics
(both inhaled and intravenous) to interact with Aβ40 peptide in a
membrane mimic environment. We also want to investigate whether
the halothane–Aβ interaction is affected by the presence of other
anesthetic with different physiochemical characteristics. We wish to
address the following questions:
(a) Does the popularly used inhaled anesthetic, isoﬂurane, interact
with Aβ40?
(b) Do intravenous anesthetics, propofol and thiopental interact
with Aβ40?
(c) Does thiopental inﬂuence Aβ–halothane interactions?
(d) Can we derive a molecular mechanism of Aβ peptide oligome-
rization due to the inﬂuence of these popularly used anesthetics?
2. Materials and methods
To understand these important questions, we have conducted a
series of NMR experiments to investigate Aβ40 peptide interactions
with isoﬂurane, propofol, thiopental and thiopental combined with
halothane.
Fig. 2. An overlay of 15N/H HSQC spectra of uniform labeled Aβ40 in SDS micelles with/
without isoﬂurane is presented. Each peak in theHSQC spectra corresponds to the amide
proton of Aβ40. The Y-axis represents the chemical shift position of 15N of the amide
proton and X-axis represents the 1H chemical shift of the amide protons. The sequence
speciﬁc assignments are performed based on different NMR experiments as mentioned
in the text. The color-coding of the amide protons represents different conditions: (1)
Only Aβ40 peptide (blue); (2) Aβ40+3 μl isoﬂurane (red); (3) Ab40+6 μl isoﬂurane
(green) and Aβ40+10 μl isoﬂurane (magenta), respectively. Critical residues involved in
Aβ oligomerization are indicated by asterisks (⁎). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Deuterated sodium dodecyl sulphate (SDSD25) (Cambridge Isotope
Laboratories), halothane (Sigma-Aldrich), isoﬂurane (Lancaster Synth-
esis Inc., USA), propofol (Sigma-Aldrich, USA), and thiopental (Abbott
Laboratories, Chicago, USA) were procured. We purchased uniformly
15N labeled Aβ40 from Recombinant Peptide Technologies (Atlanta,
GA, USA).We used a gas tight micro syringe (SGE LE Syringe, Australia)
for the addition of halothane and isoﬂurane. For anesthetic (halothane
and isoﬂurane) concentration determination, two coaxial NMR tubes
(5 mm and 3 mm) were used [9]. The chemical structure of four
anesthetics under study, i.e., halothane, isoﬂurane, propofol, and
thiopental is shown in Fig. 1. Reported molecular volumes for
halothane, isoﬂurane, propofol are 110 Å3 [10], 144 Å3 [10] and
191 Å3 [11], respectively. The molecular volume of thiopental is higher
than propofol. Halothane and isoﬂurane both are inhaled anesthetics
with similar physiochemical characteristics. Both halothane and
isoﬂurane are liquid at room temperature, similar boiling points and
hydrophobic in nature. Halothane belongs to haloalkane category and
isoﬂurane belongs to haloether category. Halothane is smaller sized
than isoﬂurane. On the other hand, propofol and thiopental are
intravenous anesthetics and both belong to non-opioid category. Both
propofol and thiopental have similar physiochemical characteristics as
propofol is rapidly redistributed like the thiopental. Propofol is a subs-
tituted phenol and thiopental contains cyclic ringwith electronegative
oxygen and sulphur atoms. Thiopental is bulkier than propofol.
2.2. Preparation of Aβ peptide solution in SDS
SDSD25 powder was added in 200 μl PBS buffer (pH 7.2), mixed
slowly and sonicated for a few seconds. One milligram uniformly 15N
labeled lyophilized powder of Aβ40 was added to SDSD25 solution and
gently mixed. A sodium 3-trimethylsilyl-[2,2,3,3-2H4]-1-propionate
(TSP) solution in D2O (50 μl) was added to the Aβ40 solution. TSP
served as a chemical shift reference and D2O provided the ﬁeld/
frequency lock for the NMR spectrometer. The ﬁnal volume of each
NMR solution containing Aβ40 was 500 μl and the concentration of
15N labeled Aβ40 peptide was 0.45 mM. The pH of the Aβ peptide
solution was adjusted and measured at 7.2 for all NMR studies before
addition of anesthetics.
2.3. Anesthetic addition to the Aβ peptide solution
For isoﬂurane, we added total 10 μl neat isoﬂurane consecutively
(3 μl, 3 μl and 4 μl respectively) to the Aβ peptide solution using an air
tight micro syringe. For propofol, 3 μl neat propofol solution wasFig. 1. The structure of four different anesthetics under study.added directly to the Aβ peptide solution followed by the addition of
another 3 μl neat propofol solution. The ﬁnal propofol concentration
was 63.98 (~64) mM. For thiopental (MW 264.321), addition of 6 μl
stock solution (400 mM) to 500 ml Aβ40 solution yields 4.8 mM
thiopental concentration. The ﬁnal thiopental solutionwas 7mMwith
the addition of 3 μl thiopental solution (400 mM).
In the combined thiopental and halothane experiments, 5 μl
thiopental stock solution (400 mM) was added ﬁrst to the Aβ peptide
solution (thiopental concentration 4 mM) and HSQC experiment was
performed. Then 4 μl halothane was added to that solution and a
HSQC experiment was performed. An additional 2 μl halothane was
further added followed by another HSQC experiment. Finally another
2 μl halothane was added, thus the solution contains 4 mM thiopental
plus 8 μl halothane and HSQC experiments performed at different
time points.
2.4. NMR experimental details and data analysis
We performed all NMR experiments using a Bruker DRX spectro-
meter operating at a proton frequency of 500.132 MHz using a 5 mM
TXI probe (Bruker, Germany). The sequence speciﬁc assignments of all
amide protons of Aβ40 at pH 7.2 were performed earlier. For each
anesthetic, ﬁrst we prepared the Aβ40 peptide solution at pH 7.2 and
added the respective anesthetic mixed gently and left anesthetic to
equilibrate followed by a HSQC experiment. All NMR data from the
Bruker instrumentwere converted into nmrPipe format and processed
using nmrPipe programs [12] using an Octane silicon graphics
computer. Data were analyzed using PIPP [13] and SPARKY [14]
programs using in-house scripts. Halothane and isoﬂurane concentra-
tions were determined using our modiﬁed experimental technique
consisting of two coaxial NMR tubes (5 mm and 3 mm) [9].
Fig. 3. Overlay of 15N/H HSQC spectra of uniform labeled Aβ40 in SDS micelles with/
without propofol is presented. Each peak in the HSQC spectra corresponds to the amide
proton of Aβ40. The Y-axis represents the chemical shift position of 15N of the amide
proton and X-axis represents the 1H chemical shift of the amide protons. The sequence
speciﬁc assignments are performed based on different NMR experiments as mentioned
in the text. The color-coding of the amide protons represents different conditions:
(1) Only Aβ40 peptide (blue); (2) Aβ40+32 mM propofol (red); (3) Aβ40+64 mM
propofol (green), respectively. Critical residues involved in Aβ oligomerization are
indicated by asterisks (⁎) sign. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Overlay of 15N/H HSQC spectra of uniform labeled Aβ40 in SDS micelles with/
without thiopental is presented. Each peak in the HSQC spectra corresponds to the
amide proton of Aβ40. The Y-axis represents the chemical shift position of 15N of the
amide proton and X-axis represents the 1H chemical shift of the amide protons. The
sequence speciﬁc assignments are performed based on different NMR experiments as
mentioned in the text. The color-coding of the amide protons represents different
conditions: (1) Only Aβ40 peptide (blue); (2) Aβ40+4.7 mM thiopental (green); (3)
Aβ40+7 mM thiopental (magenta), respectively. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Overlay of 15N/H HSQC spectra of uniformly 15N labeled Aβ40 in SDS micelles in
four different conditions: (1) Aβ40 only (blue); (2) Aβ40+4 mM thiopental (red);
(3) 4 mM thiopental+4 μl halothane (green); and 4) 4 mM thiopental+6 μl halothane
(magenta). The Y-axis represents the chemical shift positions of the amide nitrogens
(15N) and the X-axis represents the chemical shift positions of the amide protons (1H).
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
Fig. 6. Overlay of 15N/H HSQC spectra of uniformly 15N labeled Aβ40 in SDS micelles in
two different conditions: (1) Aβ40 only (blue); (2) 4mM thiopental+8 μl halothane after
28 h (red). The Y-axis represents the chemical shift positions of the amide nitrogens
(15N) and the X-axis represents the chemical shift positions of the amide protons (1H).
The additional broad amide peaksmarked by arrows indicate the oligomerization due to
halothane in the presence of thiopental. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Aβ peptide adopts a random coil conformation in aqueousmedium
which leads to a time-dependent aggregation of Aβ peptide in
aqueous solution [15–20]. It is important to note that the structure of
Aβ peptides in membranes is of high interest, as it is believed that Aβ
damages the cellular membrane resulting in a cytotoxic effect [21].
Previous ﬁndings from our laboratory demonstrated brain membrane
alterations in both AD autopsy samples and probable AD subjects [22–
28]. The SDS micelle environment provides an appropriate membrane
mimicking system for NMR studies. In the present work, we have
studied the Aβ40 interactions with isoﬂurane, propofol, thiopental
and thiopental combined with halothane in a membrane mimic SDS
medium.
3.1. Aβ peptide interactions with single anesthetics
3.1.1. Isoﬂurane interaction with Aβ40
Fig. 2 is an overlay of four HSQC spectra of uniform 15N labeled
Aβ40 with and without 3 μl, 6 μl and 10 μl isoﬂurane. These NMRFig. 7. Chemical shift changes (NH and 15N) of three residues (G29, A30 and I31) due to additio
various concentrations.experiments were designed to investigate the concentration depen-
dence of isoﬂurane interactions with Aβ40 peptide. The sequence
speciﬁc assignments of amide proton of Aβ40 (without isoﬂurane) are
shown in blue. The amide protons of Aβ40 are shown in different
colors with the addition of 3 μl (red), 6 μl (green) and 10 μl (magenta)
isoﬂurane. Changes in chemical shift due to addition of isoﬂurane
were observed for the critical amide proton of G29, A30 and I31
(Fig. 2). The isoﬂurane concentration after addition of 3 μl, 6 μl and
10 μl in a 500 μl SDS solution was found to be 26.57, 53.26 and
81.69mMas experimentally determined by 19F NMRusing two coaxial
NMR tubes (5 mm and 3 mm) [9].
3.1.2. Propofol interactions with Aβ40
Fig. 3 is an overlay of three HSQC spectra of uniform 15N
labeled Aβ40 with and without 32 mM and 64 mM propofol. The
amide protons of Aβ40 are shown in blue (without propofol) and
in the presence of 32 mM (red) and 64 mM (green) propofol
concentrations. Changes in chemical shift observed for amino acid
residues, G29, A30 and I31 were similar to Aβ40-isoﬂurane as
shown in Fig. 2.n of isoﬂurane (A), thiopental with halothane (B), propofol (C) andwith thiopental (D) at
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Fig. 4 is an overlay of three HSQC spectra; one without
thiopental (Aβ only, blue), the others with 4.8 mM (green) and
7 mM (magenta) thiopental concentrations. No change in chemical
shift was observed for critical amino acid residues, G29, A30, and
I31 due to thiopental. Aβ peptide remains in monomeric form in
the presence of 7 mM thiopental. It is very important to note that
other residues (i.e. F20, Q15 etc) show chemical shift in the
presence of isoﬂurane, thiopental and propofol.
3.2. Aβ peptide interactions with thiopental and halothane in
combination
Fig. 5 is an overlay of four HSQC spectra of uniform 15N labeled
Aβ40 without thiopental (blue), with 4 mM thiopental (red), 4 mM
thiopental+4 μl halothane(green), and 4 mM thiopental+6 μl
halothane (magenta), respectively. These NMR experiments were
designed to investigate the effect halothane on Aβ in the presence
of thiopental with different physiochemical characteristics. Changes
in chemical shift were observed for the amide protons of amino
acid residues, G29 and I31 after the addition of halothane (Fig. 5).
Fig. 6 is an overlay of two HSQC spectra of uniformly 15N labeled
Aβ40 without thiopental (blue) and with 4 mM thiopental
+56.8 mM halothane (red) after 28 h (Fig. 6). We have determined
experimentally that 4 μl, 6 μl and 8 μl halothane in 505 μl SDS
solution corresponds to 27.6, 35.35 and 56.8 mM using a recently
developed technique using 3 mm and 5 mm coaxial NMR tubes to
measure inhaled anesthetic concentration [9].
3.3. Topological evidence for Aβ peptide and anesthetics interactions
It has been suggested that anesthesia might result from
molecular interactions at the interface between aqueous and non-Fig. 8. A schematic diagram of both thiopental and halothane interactions with Aβ on the ex
than that of halothane. Hence, thiopental cannot access the critical amide protons in the
Halothane modulates these three critical residues and accelerates Aβ oligomerization in thepolar media (e.g., membrane) [29]. This suggestion is supported
by NMR and gas chromatography studies of clinical anesthetics
with macromolecular surfaces [30]. Recent progress in computa-
tional studies of membrane aqueous interfaces has made it
possible to estimate concentration proﬁles of anesthetics across
these interfaces by computer simulations [31–33]. Aβ40 peptide
is located in the membrane aqueous environment as determined
by earlier studies using backbone dynamics studies [34].
Halothane, isoﬂurane and propofol are generally located in the
membrane aqueous region [35–37]. Anesthetics and Aβ peptide
are localized in a similar domain/region and the interactions
between Aβ and anesthetics are supported due to topological
coexistence.
3.4. Oligomerization of Aβ peptide as observed by NMR spectroscopy
HSQC is an extremely powerful experiment to identify the
oligomerization of uniformly labeled peptides or proteins. Under
normal conditions, uniformly 15N labeled Aβ40 peptide (mono-
meric form) shows 40 unique amide peaks in the two-dimensional
HSQC spectra (X-axis represents amide proton (1H) chemical shift
and Y-axis represents 15N chemical shifts of Aβ peptide). The
chemical shift range of amide protons is generally 6.5 ppm to
10 ppm; however, 15N chemical shift range is generally 100 to
130 ppm. Due to wide dispersion of 15N chemical shift range,
HSQC spectrum is less crowded for a small peptide like Aβ40. In
the event of oligomerization of Aβ40, the HSQC spectra shows
additional amide peaks [38]; the intensity of these additional
peaks are generally lower because of oligomerization and slow
molecular tumbling. The number of additional amide peaks
indicates the extent of aggregation (e.g., dimeric, trimeric, tetra-
meric etc.) which exclusively depends on the system under study
[38].tracellular side of the plasma membrane. The molecular volume of thiopental is greater
loop regions of Aβ and these residues are accessible by the smaller sized halothane.
presence of thiopental.
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Proteins are potential molecular targets of anesthetics [39]. It is
reported by NMR spectroscopic studies that halothane binding results
in chemical shift change in PDZ-95 PDZ2, a neuronal protein located at
the synapses [40]. Fluorinated compounds are known to increase the
helical content of peptides, most likely by desolvating the peptide
[41,42]. Binding of the anesthetics molecules in the hydrophobic
pocket of protein is also reported [39]. It has been shown that bound
volatile general anesthetics alter both local protein dynamics and
global protein stability [36,37,43]. Aβ40 peptide has two α-helices
[α-helix-I (residues 15–23) and α-helix-II (residues 32–36)] con-
nected by a more ﬂexible kink region [44]. The dynamics of the kink
(hinge) region of Aβ peptide is altered due to interaction with
anesthetics as indicated by the profound chemical shift changes of
G29 and I31. This could bring the two helices of Aβ closer and it
might initiate the cascade of events leading to Aβ oligomerization.
NMR data indicate that isoﬂurane, propofol and halothane in the
presence of thiopental interact with the critical residues G29, A30 and
I31. On contrary, thiopental alone does not interact with these
residues. In this study, four anesthetics (halothane, isoﬂurane,
propofol and thiopental) consisting of two inhaled (halothane and
isoﬂurane) and two intravenous anesthetics (propofol and thiopental).
The physiochemical characteristics (identiﬁed by chemical structure
as well as their physical properties) of these anesthetics may play an
important role for interaction with Aβ peptide. Halothane and
isoﬂurane have similar physiochemical character and among these
two anesthetics, halothane is much smaller that isoﬂurane. So
molecular size is a factor comparing these two anesthetics. It is very
important to note that halothane (in the presence of thiopental)
induces more chemical changes of three critical residues than
isoﬂurane with similar concentration range (Fig. 7). In the case of
intravenous anesthetics, propofol and thiopental have similar physio-
chemical characteristics. Thiopental is larger than propofol and
similarly the size factor between these anesthetics may be important
for the differential pattern of interaction with Aβ peptide. This
explains why no changes in chemical shifts were observed for G29,
A30 or I31 of Aβ40 peptide with the addition of thiopental (Fig. 7).
Also, no Aβ40 oligomerization was observed in the presence of
thiopental.
The peak intensity of three peaks (G29, A30 and I31) is also
reduced signiﬁcantly due to halothane (in the presence of thiopental),
isoﬂurane and propofol (ﬁgure not shown) and G29, A30 and I31 peak
intensity did not change due to thiopental (ﬁgure not shown).
Thiopental did not interact with the three critical residues and did
not inﬂuence the interaction the halothane–Aβ interactions. A
schematic diagram [8] of anesthetic-induced Aβ oligomerization of
Aβ peptide is shown in Fig. 8. This schematic diagram is intended to
illustrate our hypothesis that anesthetics interact with Aβ peptide in
the membrane aqueous domain and induce structural changes that
lead to Aβ oligomerization. Fig. 8 also shows that due to its bulkier
size, thiopental could not ﬁt the hydrophobic pocket. Hence the
interaction of halothane with these three residues is not inﬂuenced in
the presence of thiopental. The Aβ40 structure is taken from the PDB
data bank (1BA4) [45]. To investigate the inﬂuence of anesthetic size
on Aβ oligomerization, future research with bulkier anesthetics (e.g.
midazolam, etomidate and ketamine) are warranted.
4. Conclusions
This report reveals the molecular details of Aβ peptide interactions
with several anesthetics that differ in physiochemical properties and
molecular volumes. Existing literature indicates that amyloid load is
increased in transgenic mice with halothane exposure [6]. These
animal model studies need to be extended to intravenous as well ascombination of different types of anesthetics. The NMR experimental
approach utilized in this study can be extended to other amyloid
peptides including the islet amyloid polypeptides [46–51].
The anesthetic concentrations used in our NMR studies were
higher than anesthetic concentrations used in clinical settings.
Clinically relevant concentrations of halothane and isoﬂurane are
approximately 0.3 mM [52–54]. In our NMR studies the Aβ peptide
concentration was 0.45 mM, much higher than in vivo (21±7 μM)
concentrations [5]. However, Aβ peptide concentrations used in in
vitro studies are usually ∼22 fold higher than in vivo concentrations, in
keeping with the higher anesthetic concentrations used in our
biophysical studies. Our NMR studies of Aβ peptide with different
anesthetics are being extended at clinically relevant concentrations.
Future studies with Aβ-anesthetic interactions in lipid bilayers
environment will be performed.
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